Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

2023222 citationsJournal Article

Authors

Kris V. Kowdley · Universidade Federal do Rio Grande do Sul

Christopher L. Bowlus · Universidade Federal do Rio Grande do Sul

Cynthia Levy · Universidade Federal do Rio Grande do Sul

Ulus Salih Akarca · Universidade Federal do Rio Grande do Sul

Mário Reis Álvares‐da‐Silva · Universidade Federal do Rio Grande do Sul

Pietro Andreoné · Universidade Federal do Rio Grande do Sul

Marco Arrese

Abstract

Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo. (Funded by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, NCT04526665.).

Topics & Keywords

Liver Diseases and Immunity Pediatric Hepatobiliary Diseases and Treatments Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 9, pp. 795-805

DOI: 10.1056/nejmoa2306185

Field-Weighted Citation Impact: 45.08